Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Henry Brown"'
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Autor:
Catherine Anne Eberlein, Garry Beran, Eiki Ichihara, William Pao, Zhongwu Lai, Henry Brown, Daniel Stetson, Paul R. Fisher, Jonathan R. Dry, Claire Barnes, Ambar Ahmed, Paul D. Smith, Miika Ahdesmaki, Paula J. Spitzler, Catherine B. Meador, Darren Cross, Elizabeth L. Christey O'Brien, Sarah Ross, Katherine Al-Kadhimi, Kenneth S. Thress, Laura E. Ratcliffe, Brian Dougherty, Aleksandra Markovets
Publikováno v:
Cancer Research. 75:2489-2500
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detectio
Autor:
Lenka Oplustilova, Stephen Green, Henry Brown, Claire Crafter, Cath Trigwell, Sabina Cosulich, Oona Delpuech, Jon Curwen
Publikováno v:
Cancer Research. 75:4719-4719
Two emerging mechanisms of endocrine resistance in estrogen receptor positive (ER+) breast cancers include the activation of the phosphatidylinositol 3-kinase (PI3K) / mammalian target of rapamycin (mTOR) pathway and the de-coupling of cell cycle con
Autor:
Thomas Henry Brown, C. Robin Ganellin, Graham J. Durant, Terence F. Walker, D.Anthony Rawlings, Michael E. Parsons, Robert Blakemore, John Colin Emmett
Publikováno v:
European Journal of Medicinal Chemistry. 23:53-62
A series of 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-4-pyrimidones was prepared based on cimetidine 1. The model compound 4 has modest H2-antagonist activity as shown by its ability to antagonise histamine-stimulated tachycardia in guinea pi
Publikováno v:
Fundamental and Applied Toxicology. 7:533-546
Triamterene (2,4,7-triamino-6-phenylpteridine), a widely used diuretic/antihypertensive agent with weak antifolate activity, has been found to be positive in several in vitro assays for mutagenicity. The present studies were undertaken to characteriz
Autor:
G. J. Durant, Robert Blakemore, Terence F. Walker, Michael E. Parsons, A. C. Rasmussen, P. Blurton, Thomas Henry Brown, D. A. Rawlings, Charon R. Ganellin
Publikováno v:
European Journal of Medicinal Chemistry. 24:65-72
A series of 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-4-pyrimidones was synthesised based on oxmetidine 2 , in which the methylenedioxyphenyl group of 2 was replaced by a heterocyclic ring. Good H 2 -receptor antagonist activity was retained
Publikováno v:
Annals of Otology, Rhinology & Laryngology. 72:1082-1101
Publikováno v:
Toxicology and applied pharmacology. 53(2)
Urea cycle enzyme activities may be determined through the colorimetric analysis of urea and citrulline, which are intermediates in the cycle. A new semiautomated method was used to measure the activities of carbamyl phosphate synthetase, ornithine t
Autor:
Robert Blakemore, G. J. Durant, D. A. A. Owen, Charon R. Ganellin, Thomas Henry Brown, C. A. Harvey, Michael E. Parsons, A. C. Rasmussen, G. S. Sach, D. G. Cooper, Robert John Ife
Publikováno v:
New England and regional allergy proceedings. 7(2)
SK&F 93319 (icotidine), 2-[4-(3-methoxypyrid-2-yl)butylamino]-5-[(6-methylpyrid-3-yl )-methyl]- pyrimidin-4-one trihydrochloride, has been identified as a novel agent which combines into one molecule the ability to antagonize the actions of histamine
Autor:
Julie Brown, Henry Brown
Publikováno v:
JAMA: The Journal of the American Medical Association. 192:382
Urea cycle enzymes which broadly control ammonia metabolism in the liver are being investigated after experimental portacaval shunt operations. The shunt operation has received considerable attention from clinicians because it is a definitive treatme